The TRRAP transcription cofactor represses interferon-stimulated genes in colorectal cancer cells

  1. Dylane Detilleux
  2. Peggy Raynaud  Is a corresponding author
  3. Berengere Pradet-Balade  Is a corresponding author
  4. Dominique Helmlinger  Is a corresponding author
  1. University of Montpellier, CNRS, France

Abstract

Transcription is essential for cells to respond to signaling cues and involves factors with multiple distinct activities. One such factor, TRRAP, functions as part of two large complexes, SAGA and TIP60, which have crucial roles during transcription activation. Structurally, TRRAP belongs to the PIKK family but is the only member classified as a pseudokinase. Recent studies established that a dedicated HSP90 co-chaperone, the TTT complex, is essential for PIKK stabilization and activity. Here, using endogenous auxin-inducible degron alleles, we show that the TTT subunit TELO2 promotes TRRAP assembly into SAGA and TIP60 in human colorectal cancer cells (CRC). Transcriptomic analysis revealed that TELO2 contributes to TRRAP regulatory roles in CRC cells, most notably of MYC target genes. Surprisingly, TELO2 and TRRAP depletion also induced the expression of type I interferon genes. Using a combination of nascent RNA, antibody-targeted chromatin profiling (CUT&RUN), ChIP, and kinetic analyses, we propose a model by which TRRAP directly represses the transcription of IRF9, which encodes a master regulator of interferon stimulated genes. We have therefore uncovered an unexpected transcriptional repressor role for TRRAP, which we propose contributes to its tumorigenic activity.

Data availability

The raw sequencing data reported in this publication have been deposited in NCBI Gene Expression Omnibus and are accessible through GEO Series accession number GSE171454 and GSE192527.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Dylane Detilleux

    CRBM, University of Montpellier, CNRS, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Peggy Raynaud

    CRBM, University of Montpellier, CNRS, Montpellier, France
    For correspondence
    peggy.raynaud@crbm.cnrs.fr
    Competing interests
    The authors declare that no competing interests exist.
  3. Berengere Pradet-Balade

    CRBM, University of Montpellier, CNRS, Montpellier, France
    For correspondence
    berengere.pradet-balade@crbm.cnrs.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1720-3739
  4. Dominique Helmlinger

    CRBM, University of Montpellier, CNRS, Montpellier, France
    For correspondence
    dhelmlinger@crbm.cnrs.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1501-0423

Funding

Fondation ARC pour la Recherche sur le Cancer (PJA-20181208277)

  • Dominique Helmlinger

Institut National Du Cancer (PLBIO 2016-161)

  • Berengere Pradet-Balade
  • Dominique Helmlinger

Ligue Nationale Contre le Cancer (Graduate Student Fellowship)

  • Dylane Detilleux

Ligue Nationale Contre le Cancer (Comité Hérault)

  • Peggy Raynaud

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2022, Detilleux et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,995
    views
  • 247
    downloads
  • 10
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Dylane Detilleux
  2. Peggy Raynaud
  3. Berengere Pradet-Balade
  4. Dominique Helmlinger
(2022)
The TRRAP transcription cofactor represses interferon-stimulated genes in colorectal cancer cells
eLife 11:e69705.
https://doi.org/10.7554/eLife.69705

Share this article

https://doi.org/10.7554/eLife.69705

Further reading

    1. Chromosomes and Gene Expression
    Carlos Moreno-Yruela, Beat Fierz
    Insight

    Specialized magnetic beads that bind target proteins to a cryogenic electron microscopy grid make it possible to study the structure of protein complexes from dilute samples.

    1. Chromosomes and Gene Expression
    2. Structural Biology and Molecular Biophysics
    Liza Dahal, Thomas GW Graham ... Xavier Darzacq
    Research Article

    Type II nuclear receptors (T2NRs) require heterodimerization with a common partner, the retinoid X receptor (RXR), to bind cognate DNA recognition sites in chromatin. Based on previous biochemical and overexpression studies, binding of T2NRs to chromatin is proposed to be regulated by competition for a limiting pool of the core RXR subunit. However, this mechanism has not yet been tested for endogenous proteins in live cells. Using single-molecule tracking (SMT) and proximity-assisted photoactivation (PAPA), we monitored interactions between endogenously tagged RXR and retinoic acid receptor (RAR) in live cells. Unexpectedly, we find that higher expression of RAR, but not RXR, increases heterodimerization and chromatin binding in U2OS cells. This surprising finding indicates the limiting factor is not RXR but likely its cadre of obligate dimer binding partners. SMT and PAPA thus provide a direct way to probe which components are functionally limiting within a complex TF interaction network providing new insights into mechanisms of gene regulation in vivo with implications for drug development targeting nuclear receptors.